Old Web
English
Sign In
Acemap
>
authorDetail
>
Daniel da Motta Girardi
Daniel da Motta Girardi
National Institutes of Health
Pathology
Medicine
Nivolumab
Metastatic Urothelial Carcinoma
Cabozantinib
3
Papers
2
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
A phase II study of the selective MET kinase inhibitor INC280 in advanced papillary renal cell cancer.
2020
Journal of Clinical Oncology
Paul Denis Leger
Daniel da Motta Girardi
Munjid Al Harthy
Julia C. Friend
Lisa Mac
Erin Purcell
Cathy D. Vocke
Sandeep Gurram
Maria J. Merino
Peter L. Choyke
W. Marston Linehan
Ramaprasad Srinivasan
Show All
Source
Cite
Save
Citations (0)
Ipilimumab challenge/re-challenge in metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors treated with cabozantinib+nivolumab (CaboNivo) or cabozantinib+nivolumab+ipilimumab (CaboNivoIpi).
2020
Journal of Clinical Oncology
Scot Anthony Niglio
Daniel da Motta Girardi
Amir Mortazavi
Primo Lara
Sumanta K. Pal
Biren Saraiya
Lisa M. Cordes
Lisa Ley
Olena Sierra Ortiz
Jacqueline Cadena
Carlos Díaz
Mohammadhadi Bagheri
Seth M. Steinberg
Rene Costello
Howard Streicher
John Wright
Howard L. Parnes
Yang Min Ning
Donald P. Bottaro
Andrea B. Apolo
Show All
Source
Cite
Save
Citations (2)
Phase I expansion study of cabozantinib plus nivolumab (CaboNivo) in metastatic urothelial carcinoma (mUC) patients (pts) with progressive disease following immune checkpoint inhibitor (ICI) therapy.
2020
Journal of Clinical Oncology
Daniel da Motta Girardi
Scot Anthony Niglio
Amir Mortazavi
Primo Lara
Sumanta K. Pal
Biren Saraiya
Lisa M. Cordes
Lisa Ley
Olena Sierra Ortiz
Jacqueline Cadena
Carlos Díaz
Mohammadhadi Bagheri
Seth M. Steinberg
Rene Costello
Howard Streicher
John Wright
Howard L. Parnes
Yang Min Ning
Donald P. Bottaro
Andrea B. Apolo
Show All
Source
Cite
Save
Citations (0)
1